This site is intended for healthcare professionals
Abstract digital waveforms in blue and purple
FDA Drug information

Lamotrigine

Read time: 1 mins
Marketing start date: 23 Dec 2024
...
 

Summary of product characteristics


Effective Time

20230926

Version

10

Spl Product Data Elements

Lamotrigine Lamotrigine LAMOTRIGINE LAMOTRIGINE LACTOSE MONOHYDRATE MAGNESIUM STEARATE SODIUM STARCH GLYCOLATE TYPE A POTATO POVIDONE CELLULOSE, MICROCRYSTALLINE WHITE TO OFF- WHITE ROUND ZC;79 Lamotrigine Lamotrigine LAMOTRIGINE LAMOTRIGINE LACTOSE MONOHYDRATE MAGNESIUM STEARATE SODIUM STARCH GLYCOLATE TYPE A POTATO POVIDONE CELLULOSE, MICROCRYSTALLINE WHITE TO OFF- WHITE ROUND ZC;90 Lamotrigine Lamotrigine LAMOTRIGINE LAMOTRIGINE LACTOSE MONOHYDRATE MAGNESIUM STEARATE SODIUM STARCH GLYCOLATE TYPE A POTATO POVIDONE CELLULOSE, MICROCRYSTALLINE WHITE TO OFF- WHITE ROUND ZC;80 Lamotrigine Lamotrigine LAMOTRIGINE LAMOTRIGINE LACTOSE MONOHYDRATE MAGNESIUM STEARATE SODIUM STARCH GLYCOLATE TYPE A POTATO POVIDONE CELLULOSE, MICROCRYSTALLINE WHITE TO OFF- WHITE ROUND ZC;81 Lamotrigine Lamotrigine LAMOTRIGINE LAMOTRIGINE LACTOSE MONOHYDRATE MAGNESIUM STEARATE SODIUM STARCH GLYCOLATE TYPE A POTATO POVIDONE CELLULOSE, MICROCRYSTALLINE WHITE TO OFF- WHITE ROUND ZC;82 Lamotrigine Lamotrigine LAMOTRIGINE LAMOTRIGINE LACTOSE MONOHYDRATE MAGNESIUM STEARATE SODIUM STARCH GLYCOLATE TYPE A POTATO POVIDONE CELLULOSE, MICROCRYSTALLINE WHITE TO OFF- WHITE ROUND ZC;91 Lamotrigine Lamotrigine LAMOTRIGINE LAMOTRIGINE ASPARTAME CROSCARMELLOSE SODIUM MAGNESIUM STEARATE MANNITOL TRIBASIC CALCIUM PHOSPHATE SILICON DIOXIDE CELLULOSE, MICROCRYSTALLINE BLACK CURRANT WHITE TO OFF- WHITE Black Current ROUND Z;13 Lamotrigine Lamotrigine LAMOTRIGINE LAMOTRIGINE ASPARTAME CROSCARMELLOSE SODIUM MAGNESIUM STEARATE MANNITOL TRIBASIC CALCIUM PHOSPHATE SILICON DIOXIDE CELLULOSE, MICROCRYSTALLINE BLACK CURRANT WHITE TO OFF- WHITE Black Current ROUND Z;12

Application Number

ANDA077633

Brand Name

Lamotrigine

Generic Name

Lamotrigine

Product Ndc

65841-686

Product Type

HUMAN PRESCRIPTION DRUG

Route

ORAL

Package Label Principal Display Panel

PACKAGE LABEL.PRINCIPAL DISPLAY PANEL Lamotrigine Tablets (Chewable, Dispersible), 5 mg NDC 65841-689-01 in bottle of 100 tablets 100 tablets Rx only Lamotrigine Tablets (Chewable, Dispersible), 5 mg Lamotrigine Tablets (Chewable, Dispersible), 25 mg NDC 65841-690-01 in bottle of 100 tablets 100 tablets Rx only Lamotrigine Tablets (Chewable, Dispersible), 25 mg Lamotrigine Tablets USP, 25 mg NDC 65841-682-01 in bottle of 100 tablets 100 tablets Rx only Lamotrigine Tablets USP, 25 mg Lamotrigine Tablets USP, 50 mg NDC 65841-683-01 in bottle of 100 tablets 100 tablets Rx only Lamotrigine Tablets USP, 50 mg Lamotrigine Tablets USP, 100 mg NDC 65841-684-01 in bottle of 100 tablets 100 tablets Rx only Lamotrigine Tablets USP, 100 mg Lamotrigine Tablets USP, 150 mg NDC 65841-685-14 in bottle of 60 tablets 60 tablets Rx only Lamotrigine Tablets USP, 150 mg Lamotrigine Tablets USP, 200 mg NDC 65841-686-14 in bottle of 60 tablets 60 tablets Rx only Lamotrigine Tablets USP, 200 mg Lamotrigine Tablets USP, 250 mg NDC 65841-687-05 in bottle of 500 tablets 500 tablets Rx only Lamotrigine Tablets USP, 250 mg Lamotrigine Tablets (Chewable, Dispersible), 5 mg Lamotrigine Tablets (Chewable, Dispersible), 5mg Lamotrigine Tablets (Chewable, Dispersible), 25 mg Lamotrigine Tablets USP, 25 mg Lamotrigine Tablets USP, 50 mg Lamotrigine Tablets USP, 100 mg Lamotrigine Tablets USP, 150 mg Lamotrigine Tablets USP, 200 mg Lamotrigine Tablets USP, 250 mg

Spl Medguide

SPL MEDGUIDE

Drug section

CME banner

Learning Zones

The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.

Click here to view

Disclaimer

The drug Prescribing Information (PI), including indications, contra-indications, interactions, etc, has been developed using the U.S. Food & Drug Administration (FDA) as a source (www.fda.gov).

Medthority offers the whole library of PI documents from the FDA. Medthority will not be held liable for explicit or implicit errors, or missing data.

Drugs appearing in this section are approved by the FDA. For regions outside of the United States, this content is for informational purposes only and may not be aligned with local regulatory approvals or guidance.